home / stock / vacc / vacc news

VACC News and Press, Vaccitech plc From 03/24/23

Stock Information
Company Name: Vaccitech plc
Stock Symbol: VACC
Market: NASDAQ
Menu
VACC VACC Quote VACC Short VACC News VACC Articles VACC Message Board
Get VACC Alerts

News, Short Squeeze, Breakout and More Instantly...
VACC - AEVA, RBOT and OXBR among mid-day movers

2023-03-24 12:20:59 ET Gainers: Silvergate Capital Corporation ( SI ) +66% . NaaS Technology ( NAAS ) +36% . Assure Holdings ( IONM ) +21% . Dermata Therapeutics ( DRMA ) +21% . ReNew Energy Global ( RNW ) +20% . GH Research ...
VACC - Dermata, GH Research top healthcare gainers; BridgeBio, Cidara among losers

2023-03-24 10:01:43 ET Gainers: Dermata Therapeutics ( DRMA ) +40% . GH Research ( GHRS ) +27% . Vaccitech ( VACC ) +25% . Cosmos Health ( COSM ) +10% . Assure ( IONM ) +6% . Losers: BridgeBio Pharma ( BBIO ) -9%...

VACC - Vaccitech GAAP EPS of $0.14, revenue of $44.7M

2023-03-24 09:39:49 ET Vaccitech press release ( NASDAQ: VACC ): FY GAAP EPS of $0.14. Revenue of $44.7M (+14800.0% Y/Y). For further details see: Vaccitech GAAP EPS of $0.14, revenue of $44.7M

VACC - Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, au...
VACC - ZyVersa, Aziyo top healthcare gainers; Cidara, Protagenic among losers

2023-03-23 10:06:23 ET Gainers: ZyVersa Therapeutics ( ZVSA ) +33% . Aziyo Biologics ( AZYO ) +29% . Generation Bio ( GBIO ) +20% . HTG Molecular Diagnostics ( HTGM ) +16% . scPharmaceuticals ( SCPH ) +15% . Losers:...

VACC - Vaccitech's VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions

VTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs) Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6 antigens used in VTP-200 HPV001 clinical trial will continue as planned to the 1...

VACC - Vaccitech appoints new Chief Scientific Officer

Vaccitech ( NASDAQ: VACC ) appoints industry veteran Nadège Pelletier, Ph.D., as Chief Scientific Officer succeeding Tom Evans, who is retiring but will remain involved as a scientific consultant to the company. Most recently, Dr. Pelletier served at Novarti...
VACC - Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer

Dr. Pelletier joins leadership team to continue the advancement of Vaccitech’s diverse clinical pipeline and partnerships, bringing more than 15 years’ experience in pharmaceuticals and academia in immunology and infectious diseases Former CSO, Dr. Tom Evans to continu...

VACC - Vaccitech to Host KOL Webinar on the SNAPvax(TM) Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

OXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic immunotherapies for celiac disease and other autoimmune diseases on...

VACC - Vaccitech GAAP EPS of $0.22, revenue of $6.17M

Vaccitech press release ( NASDAQ: VACC ): Q3 GAAP EPS of $0.22. Revenue of $6.17M. As of September 30, 2022, cash and cash equivalents were $200.1 million, compared to $214.1 million as of December 31, 2021. For further details see: Vaccitech GAAP EPS of $0.2...
Previous 10 Next 10